Abstract: Disclosed are a polyethylene glycol conjugate drug, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a polyethylene glycol conjugate drug represented by formula A or a pharmaceutically acceptable salt thereof, a method for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, and the use of the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof in the preparation of a drug.

Abstract: The present invention relates to the technical field of medicines, and relates to a polyethylene glycol conjugated drug, a preparation method therefor and the use thereof. In particular, the present invention relates to a polyethylene glycol conjugated drug as shown in formula I or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug.

Abstract: A polyethylene glycol conjugate drug synergist, a preparation method therefor, and use thereof, specifically relating to a polyethylene glycol conjugate drug synergist as shown in formula I or a pharmaceutically acceptable salt thereof, a preparation method for the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylent glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, a composition containing the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof in preparation of a drug.

Abstract: The present invention relates to a polyethylene glycol conjugate medicament, a preparation method therefor and use thereof, and in particular relates to a polyethylene glycol conjugate medicament represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and an intermediate of the same, a pharmaceutical composition comprising the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and use thereof in preparing a medicament.

Abstract: The present invention relates to the technical field of medicines, and relates to a polyethylene glycol conjugated drug, a preparation method therefor and the use thereof. In particular, the present invention relates to a polyethylene glycol conjugated drug as shown in formula I or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug.

Abstract: The present invention relates to a polyethylene glycol conjugate medicament, a preparation method therefor and use thereof, and in particular relates to a polyethylene glycol conjugate medicament represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and an intermediate of the same, a pharmaceutical composition comprising the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and use thereof in preparing a medicament.

Abstract: The disclosure relates to the technical field of medicine, specifically to a polyethylene glycol conjugated drug, a preparation method therefor and use thereof, and relates in particular to a polyethylene glycol conjugated drug represented by formula (I) or a pharmaceutically acceptable salt thereof. The disclosure further relates to a method for preparation of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof in preparation of a medicament.

Abstract: The present disclosure belongs to the field of livestock molecular biotechnology, and provides kits and methods for pedigree division and paternity testing of domestic pigs. The kits and methods specifically select 14 SSR loci of domestic pigs, especially Anqing six-end-white pigs, and synthesize primers for corresponding loci. Through capillary electrophoresis detection of the ear tissue DNA of 98 Anqing six-end-white pigs, the count of effective alleles, heterozygosity, polymorphism information content, and genetic distance, and exclusion probability at each locus are calculated, the pedigree division of domestic pigs, especially Anqing six-end-white pigs, and paternity testing are conducted. The cumulative exclusion probability of 14 microsatellite loci is 99%.

Abstract: The disclosure relates to the technical field of medicine and in particular to a polyethylene glycol conjugated drug of formula I or a pharmaceutically acceptable salt thereof. The disclosure further relates to a method for preparation and an intermediate of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof in preparation of a medicament.

Abstract: A pixel circuit, a semiconductor camera detection circuit and a display device. The pixel circuit includes: a photodiode, a driving circuit, an initialization circuit, a transmission circuit, a voltage write-in circuit (2 and a compensation circuit. One end of the photodiode is electrically connected to a grounding end, and another end is electrically connected to the transmission circuit; the initialization circuit is configured to pull a voltage of a first node to an initialization voltage under control of the initialization signal end; the transmission circuit is configured to pull down the voltage of the first node from the initialization voltage to a data voltage under control of the first scanning signal end; the voltage write-in circuit is configured to write the data voltage into the driving circuit and output a grounding voltage to the compensation circuit; the compensation circuit is configured to perform threshold voltage compensation on the driving circuit.

Abstract: A system and method for improving electrochemical power sources through the dispensing encapsulation and dispersion into galvanic chambers of an electrochemical cell. Features of the method include the optimization of the concentration levels of chemicals involved in desired energy producing reactions.

Abstract: A system and method for improving electrochemical power sources through the dispensing, encapsulation and dispersion into galvanic chambers of an electrochemical cell. Features of the method include the optimization of the concentration levels of chemicals involved in desired energy producing reactions.

Abstract: A system and method for improving electrochemical power sources through the dispensing encapsulation and dispersion into galvanic chambers of an electrochemical cell. Features of the method include the optimization of the concentration levels of chemicals involved in desired energy producing reactions.

Abstract: A method for the formation of regular-shaped silver crystals through a wet chemical reaction (Tollen's reaction) is presented. The growth of the Ag crystals (size, morphology and aggregation) can be controlled via adjusting reaction conditions such as temperature and reducing agent concentrations before and during the reactions. The smaller Ag crystals (50-200 nm) were generated under the condition of limited reductive reagent (glucose), and the larger sliver crystals (˜5 ?m) were the aggregated silver nano-particles (100-200 nm) produced at higher reducing agent concentrations. Most of the larger crystals were in the shape of cube or rectangular cube, and rarely, they were in clusters. The smaller crystals (aggregation of Ag atoms) were shaped in cube or/and cone, and both single crystals and clusters were formed. The presence of impurity (TiO2 nano-particles, 25-50 nm) as crystal seeds enables the 3-D growth of large, irregular-shaped Ag clusters (˜5 ?m).

Abstract: The instant invention provides for a gas purification system in which a reaction chamber combines with catalysts and heating to oxidize and reduce the compounds contained in a gas stream to oxygen and other non-deleterious components. By use of this system closed loop air systems can be effectively supplied with oxygen by chemically converting the volatile organic components to desired gasses and thereby remove unwanted contaminants.

Abstract: A method for making a patterned SiO2 films over TiO2 (Si02/Ti02) under ambient atmospheric conditions, including room temperature, through photo and chemical reactions. The method is simple, convenient and can be performed in a short period of time, typically less than two hours. The patterned TiO2 film is fabricated through photo-irradiation of a photosensitive organic-titanium film using a mask. Silica particles are generated from silicate solution by adjusting pH values to 10 to 8 with hydrochloric acid. The pre-deposited TiO2 film has a strong attraction for the SiO2 particles, leading to the instant formation of SiO2 film over the TiO2 film. The silica films are also amino-silylated with 3-aminopropyltriethoxysilane toward applications such as patternable, location-specific silica-based separation and purification.

Abstract: A method for making a patterned SiO2 films over TiO2 (SiO2/TiO2) under ambient atmospheric conditions, including room temperature, through photo and chemical reactions. The method is simple, convenient and can be performed in a short period of time, typically less than two hours. The patterned TiO2 film is fabricated through photo-irradiation of a photosensitive organic-titanium film using a mask. Silica particles are generated from silicate solution by adjusting pH values to 10 to 8 with hydrochloric acid. The pre-deposited TiO2 film has a strong attraction for the SiO2 particles, leading to the instant formation of SiO2 film over the TiO2 film. The silica films are also amino-silylated with 3-aminopropyltriethoxysilane toward applications such as patternable, location-specific silica-based separation and purification.

Abstract: The instant invention provides for a gas purification system in which a reaction chamber combines with catalysts and heating to oxidize and reduce the compounds contained in a gas stream to oxygen and other non-deleterious components. By use of this system closed loop air systems can be effectively supplied with oxygen by chemically converting the volatile organic components to desired gasses and thereby remove unwanted contaminants.

Abstract: A method for the formation of regular-shaped silver crystals through a wet chemical reaction (Tollen's reaction) is presented. The growth of the Ag crystals (size, morphology and aggregation) can be controlled via adjusting reaction conditions such as temperature and reducing agent concentrations before and during the reactions. The smaller Ag crystals (50-200 nm) were generated under the condition of limited reductive reagent (glucose), and the larger sliver crystals (˜5 ?m) were the aggregated silver nano-particles (100-200 nm) produced at higher reducing agent concentrations. Most of the larger crystals were in the shape of cube or rectangular cube, and rarely, they were in clusters. The smaller crystals (aggregation of Ag atoms) were shaped in cube or/and cone, and both single crystals and clusters were formed. The presence of impurity (TiO2 nano-particles, 25-50 nm) as crystal seeds enables the 3-D growth of large, irregular-shaped Ag clusters (˜5 ?m).